JOHANNESBURG, March 3 (Reuters) – Aspen Pharmacare’s unbranded version of Novo Nordisk’s popular diabetes drug Ozempic could be registered in Canada in the second or third quarter of this year, the South African pharmacueticals group’s CEO said on Tuesday.
“We’re getting feedback from the regulators. From what we can see, we could have a registration in late Q2 or Q3 of this calendar year, so some time between May and September,” Stephen Saad told Reuters.
Aspen hopes to be one of the first to provide generic competition for Ozempic in Canada after Novo’s patent on semaglutide for diabetes expired in January.
(Reporting by Nqobile DludlaEditing by David Goodman)
Brought to you by www.srnnews.com